Figure EV1. LIF exhibits therapeutic effects in the wild‐type mouse colitis model and shows minor effect on Th1‐, Th2‐, or Treg‐cell differentiation.

• A, B
  Quantitative expression of Lifr and gp130 mRNA in colon tissue from DSS‐challenged or control mice (n = 6 per group) (A) or in IECs following stimulation by LPS (2.5 μg/ml), PGN (3 μg/ml), or LTA (2 μg/ml) for 2 h (B).
• C
  Macroscopic changes in the colon of WT and Stat4‐KO mice on day 14 of colitis induction.
• D
  FACS staining of LPLs isolated on day 10 from the colon of WT and Stat4‐KO colitis mice receiving PBS or LIF (n = 4 per group). The percentage of IL‐17A⁺ (left) and IFNγ⁺CD4⁺ (right) T cells in vivo was analyzed.
• E
  FACS staining of WT and Stat4‐KO naïve CD4⁺ T cells treated or not treated with LIF on day 4 of induction into Th1‐, Th2‐, or Treg‐cell subsets.
• F, G
  qPCR analysis of Th1, Th2, or Treg signature gene expression in WT and Stat4‐KO naïve CD4⁺ T cells on day 4 of induction into the indicated subsets in the absence or presence of LIF. The data are representative of three independent experiments.

Data information: *P < 0.05, **P < 0.01, and ***P < 0.001, ns: not significant (Student's t‐test). Error bars represent the SEM.